KEYNOTE-100: Final Results From Phase II Study on Pembrolizumab Monotherapy for Advanced Recurrent Ovarian Cancer

May 29-31, 2020; Online at
Pembrolizumab monotherapy resulted in ORR of 8.5% with median DoR of 10.2 mos and median OS of 18.7 mos in patients with advanced recurrent ovarian cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 321 KB
Released: June 8, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

From Clinical Care Options (CCO), Webcast and downloadable slides reviewing the latest data on the use of PARP inhibitors to treat newly diagnosed advanced ovarian cancer

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci
Program Director
person default Alexandra Leary, MD, PhD person default Frederik Marmé, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: February 19, 2021 Expired: February 18, 2022

On-demand Clinical Care Options (CCO) Webcast that reviews the latest clinical data informing the optimal management of patients with ovarian cancer from an expert global perspective.

Antonio Gonzalez-Martin, MD, PhD Ursula Matulonis, MD Prof Ignace Vergote Released: February 11, 2021

Expert commentary on the use of PARP inhibitors as frontline maintenance therapy in the treatment of ovarian cancer, from Clinical Care Options

Ursula Matulonis, MD Released: January 11, 2021

In this slideset, CCO’s expert faculty explores the role of biomarkers and HRD when treating patients with ovarian cancer using PARP inhibitors

person default Alexandra Leary, MD, PhD Released: December 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.